Evaluating the Rockwood Clinical Frailty Score in patients with cardiogenic shock
Prognostic Value of the Rockwood Clinical Frailty Score in Cardiogenic Shock
This study is testing if the Rockwood Clinical Frailty Score can help doctors better predict outcomes for adults in the ICU who are experiencing cardiogenic shock.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06692855 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prognostic value of the Rockwood Clinical Frailty Score in patients experiencing cardiogenic shock. It focuses on adult patients hospitalized in an Intensive Care Unit from January 2014 to September 2024, utilizing existing data to evaluate the effectiveness of this frailty score in predicting patient outcomes. The study seeks to improve the stratification of cardiogenic shock severity, which is crucial for timely and effective management. By comparing the Rockwood score with existing prognostic tools, the study aims to identify a more efficient method for assessing patient risk at the bedside.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are hospitalized with cardiogenic shock.
Not a fit: Patients who have opted out of data reuse for research purposes or those under legal guardianship may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk stratification and management of patients with cardiogenic shock.
How similar studies have performed: While there are existing prognostic scores for cardiogenic shock, the effectiveness of the Rockwood Clinical Frailty Score in this context is being evaluated for the first time.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (≥18 years) * Patient with cardiogenic shock according to ESC 2021 definition * Patient hospitalized from January 1, 2014 to September 1, 2024 in an Intensive Care Unit * Patients who do not object to the re-use of their data for the purposes of this research. Criteria Exclusion: * Patient having expressed his opposition to the re-use of his data for scientific research purposes. * Subject under court protection. * Subject under guardianship or curatorship.
Where this trial is running
Strasbourg
- Service de Médecine Intensive - Réanimation - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Hamid MERDJI, MD
- Email: hamid.merdji@chru-strasbourg.fr
- Phone: 33 3 69 55 11 23
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.